1. Introduction {#sec1-molecules-21-01056}
===============

Life on planet Earth owes its existence to chirality or handedness. Chiral molecules are those that possess handedness, i.e., in simple terms, they are either left handed or right handed. Only one type of handedness is preferred by the biological molecules that control the life machinery. L-amino acids and D-sugars, are the chiral constituents of proteins and nucleic acids that make up biological systems. As a consequence of the preferential dominance of chirality, drugs that are developed for the treatment of human diseases or upkeep of human health, have to possess the correct handedness. Determination of the handedness of chiral molecules, also referred to as the determination of absolute configuration (AC), has become an important research area. Chiroptical Spectroscopy \[[@B1-molecules-21-01056],[@B2-molecules-21-01056]\] is becoming an invaluable tool for this purpose.

Historically the AC determination was accomplished using X-ray crystallography, nuclear magnetic resonance (NMR) or stereoselective synthetic schemes. These three methods require, respectively, good quality crystals, diastereomeric complexes and labor-intensive chemical synthetic procedures. These disadvantages are avoided in chiroptical spectroscopic applications, where investigations on native samples in solution phase (or vapor phase in favorable situations) can be directly undertaken.

Optical rotation (OR) in the visible spectral region is one chiroptical property that elicited interest in the early days \[[@B3-molecules-21-01056]\]. When normalized with concentration (in g·cc^−1^) and pathlength (in dm), the resulting quantity is referred to as Specific rotation (SR), or specific optical rotation (SOR) as it is called in the recent literature. SOR is normally considered to be a molecular property that is independent of concentration, although exceptions are known \[[@B4-molecules-21-01056]\]. In the older literature, attempts were made to correlate SOR with AC, mostly via empirical models, but they did not survive the test of time. Circular dichroism (CD) associated with electronic transitions, referred to as electronic CD (ECD), is another chiroptical property that was popularized among synthetic organic chemists by Nakanishi, Harada, Berova, and their coworkers, via the use of an exciton chirality model \[[@B5-molecules-21-01056],[@B6-molecules-21-01056]\]. The scope of this approach is limited to molecules that possess two interacting electronic chromophores that absorb light in the visible spectral regions. A large array of chiral molecules, that do not contain electronic chromophores absorbing visible light, cannot be studied using this method. This limitation was overcome by the development of two new methods that measure optical activity associated with vibrational transitions, which do not depend on the absence or presence of electronic chromophores. One method utilizes the CD associated vibrational transitions, referred to as vibrational CD (VCD) \[[@B7-molecules-21-01056]\] and the other utilizes the differential vibrational Raman scattering referred to as vibrational Raman optical activity (VROA) \[[@B8-molecules-21-01056],[@B9-molecules-21-01056]\]. These two vibrational transition-based methods are applicable for all chiral molecules. The four methods, namely, SOR, ECD, VCD and VROA, are collectively categorized as chiroptical spectroscopic methods. The advances in chiroptical spectroscopic instrumentation and the availability of commercial instruments allowed many new researchers to undertake these measurements.

The experimental data obtained with any or all four of the chiroptical methods mentioned in the previous paragraph, however, cannot by themselves directly reveal the ACs of chiral molecules. These experimental data must be analyzed with theoretical predictions of corresponding chiroptical properties to infer the ACs.

The theoretical methods used for predicting chiroptical properties can range from approximate models to semi empirical methods and to modern quantum chemical (QC) methods. The predictions resulting from approximate models and semi empirical methods are not reliable enough for determining the ACs. Due to the revolutionary developments that took place in QC theories \[[@B10-molecules-21-01056],[@B11-molecules-21-01056],[@B12-molecules-21-01056]\], theoretical predictions resulting from the QC calculations are providing high enough confidence to reliably analyze the experimental data. The availability of software to undertake the QC calculations, and of fast computer processors to expedite the calculations has made the applications of chiroptical spectroscopic methods routine in recent years.

The current practice of determining the ACs of chiral molecules involves experimental measurement of chiroptical properties for the chemical substance of interest and undertaking QC calculations for possible structures of the molecules making up that substance. These two steps are followed by comparative analysis of the experimental and predicted chiroptical spectra.

2. Chiroptical Spectroscopic Tools {#sec2-molecules-21-01056}
==================================

In three of the following sub-sections, the instrumentation needed for experimental measurements and software used for QC predictions and spectral comparison analysis are summarized, to facilitate the introduction to newcomers. The fourth subsection illustrates a detailed procedure for AC determination.

2.1. Instrumentation {#sec2dot1-molecules-21-01056}
--------------------

The instrumentation for optical rotation measurements for liquid samples is well established and commercial instruments are available (from Jasco Inc., Easton, MD, USA and Rudolph Research Analytical Inc., Hackettstown, NJ, USA). These instruments, which cost under \$20,000, provide a measurement accuracy of 2 mdeg which is sufficient for most typical cases. Commercial laser polarimeters (from PDR Chiral Inc., Lake Park, FL, USA), which cost about \$40,000, provide a measurement accuracy of 20 μdeg, and are mostly used with chromatography applications. Optical rotation measurements for gas phase samples can be undertaken using specialized instruments that use cavity ring down methods \[[@B13-molecules-21-01056],[@B14-molecules-21-01056],[@B15-molecules-21-01056]\]. However, these instruments are quite expensive and are currently limited to academic laboratories. The instrumentation for ECD measurements for liquid samples is well established and commercial instruments are available (from Jasco Inc., Olis Inc., Bogart, GA, USA; Applied Photophyscis Inc., Leatherhead, Surrey, UK). These instruments cost \~\$150,000. The instrumentation for VCD measurements for liquid samples is well established and commercial instruments (from Jasco Inc., Bruker Inc., Billerica MA, USA; BioTools Inc., Jupiter, FL, USA) cost under \~\$200,000. The instrumentation for VROA measurements for liquid samples is also well established and currently there is only one commercial instrument (from BioTools Inc.), which costs \~\$275,000.

2.2. QC Software {#sec2dot2-molecules-21-01056}
----------------

QC calculations of chiroptical properties can be undertaken on a variety of computer platforms, ranging from desktop computers to supercomputing clusters, using commercially available as well as freeware software. Freeware packages include DALTON \[[@B16-molecules-21-01056]\], Psi4 \[[@B17-molecules-21-01056]\] and NWChem \[[@B18-molecules-21-01056]\], while popular commercial software packages include Gaussian \[[@B19-molecules-21-01056]\] and ADF \[[@B20-molecules-21-01056]\].

2.3. Spectral Comaprison Software {#sec2dot3-molecules-21-01056}
---------------------------------

Spectral comparison involves comparing the digital experimental spectra with corresponding predicted spectra using spectral overlap integral methods \[[@B21-molecules-21-01056],[@B22-molecules-21-01056]\]. A general purpose freeware program, *CDSpecTech*, has been developed in the author's laboratory, to analyze the ECD, VCD and/or VROA spectra, corresponding absorption/Raman spectra and also their ratio spectra \[[@B23-molecules-21-01056]\]. *SpecDis*, a program restricted to the analysis of ECD and corresponding absorption spectra, is also a freeware program \[[@B24-molecules-21-01056]\]. *CompareVOA* (from BioTools Inc.) is a commercial program for analyzing the VCD and corresponding absorption spectra \[[@B25-molecules-21-01056]\].

2.4. A Step-by-Step Guide for AC Determination {#sec2dot4-molecules-21-01056}
----------------------------------------------

Centratherin (see [Figure 1](#molecules-21-01056-f001){ref-type="fig"}), a natural product with anti-inflammatory and anti-microbial properties, will be used in this article as an example to lead the reader through different steps involved in the AC determination \[[@B26-molecules-21-01056]\].

The experimental chiroptical spectral data are obtained for the sample of interest dissolved in an appropriate solvent. If the solvent used does not participate in solute-solvent intermolecular hydrogen bonds, then corresponding QC calculations can be handled, relatively easily, with implicit solvation models. If intermolecular hydrogen bonding between solvent and solute is involved, then corresponding QC calculations need to incorporate explicit solvent molecules to effectively incorporate solvent effects into the calculations. The use of solvents that do not participate in intermolecular hydrogen bonding are to be favored, unless the goal is to unravel the intermolecular hydrogen bonding itself. Nevertheless, experimental measurements in different solvents at different concentrations are useful to assess the influence of solvents and concentrations.

The experimental ECD and VCD spectra and corresponding absorption spectra for centratherin measured in acetonitrile solvent \[[@B26-molecules-21-01056]\] are shown in [Figure 2](#molecules-21-01056-f002){ref-type="fig"} and [Figure 3](#molecules-21-01056-f003){ref-type="fig"}, respectively. The experimental ROA spectra could not be measured for centratherin due to fluorescence issues and lack of the availability of enough sample. The experimentally measured SOR for centratherin \[[@B26-molecules-21-01056]\] at 589 nm is −12 deg·cc·g^−1^·dm^−1^. Since the sample used for experimental measurements has negative SOR at 589 nm, this sample will be labeled as (−)~589~-centratherin.

Once a reliable set of experimental data has been gathered, QC calculations of chiroptical properties are initiated. The basic requirement for theoretical predictions of chiroptical properties is that the correct chemical structure of the compound of interest is known. Here chemical structure is meant to represent the chemical composition (atomic constituents) and the atomic connectivities (which atom is connected to which). Given that information, the three dimensional arrangement of atoms in a chiral molecule is the question that will be addressed by chiroptical spectroscopy. The three dimensional arrangement of atoms in a chiral molecule is defined by the ACs at individual chiral centers and dihedral conformations. Quite often, the relative ACs of the chiral centers may have been determined in the literature. If relative ACs are known with definite certainty, then theoretical predictions can be undertaken for that one diasteromer and conformational analysis conducted to predict the chiroptical properties. For situations where there is no prior information on the ACs of individual chiral centers, one would need to consider all possible diastereomers (and dihedral conformations associated with each diastereomer) and predict the chiroptical properties for all those possibilities. For a compound possessing "n" sources of chirality there will be 2^n^ diasteromers. Here, a source represents many of the types of chirality (for example, central chirality, axial chirality, etc.). One needs to consider 2^n−1^ diastereomers for theoretical predictions, because one-half of the 2^n^ diastereomeric structures are mirror images of the other half and their chiroptical properties would be opposite of the other half. For compounds possessing multiple sources of chirality, this situation can turn into a computational nightmare. More often than not, ACs for some of the chiral centers may have already been determined by other means (such as NOEs from NMR spectra), which will permit fixing the ACs at certain centers in the molecule, thereby reducing the computational demand.

The relative AC of centratherin (see [Figure 1](#molecules-21-01056-f001){ref-type="fig"}) is known from the literature as (6*R*,7*R*,8*S*,10*R*,2'*Z*), and therefore this disatereomer was used for the theoretical calculations \[[@B26-molecules-21-01056]\].

The first step in the process for theoretical predictions is to build a molecular model. This involves pre-defining the chirality at individual chiral centers (and axial chirality, if one is involved) of the molecule of interest. There are several molecular visualization programs that can be used to build the molecular models. A popular freeware program is Avogadro \[[@B27-molecules-21-01056]\]. Then a conformational search is carried out for the starting structure. A variety of commercial conformational search programs (Spartan \[[@B28-molecules-21-01056]\], Conflex \[[@B29-molecules-21-01056]\], Hyperchem \[[@B30-molecules-21-01056]\], Macromodel \[[@B31-molecules-21-01056]\]) are available for this purpose. It is important to make sure that all of the conformations found belong to the same diastereomer. If some conformers are found to have altered ACs then they need to be appropriately modified before further processing. The conformations determined with conformational search programs, within 20 kcal/mol of energy, need to be further refined using QC programs via geometry optimization options. A good compromise for the QC level of theory to be used here is B3LYP functional and 6-31G\* basis set. The energies of optimized geometries at this level are compared and the lowest energy conformers within a certain energy range are retained for further geometry optimization at a higher level of theory. It is important to verify that the optimized conformers are at the minimum of potential energy, by performing vibrational frequency calculations and ensuring that there are no imaginary vibrational frequencies.

For the (6*R*,7*R*,8*S*,10*R*,2'*Z*) structure, sixteen lowest energy conformations, within 3 kcal/mol range at B3LYP/6-31G\* level were reoptimized at B3LYP/aug-cc-pVDZ level of theory \[[@B26-molecules-21-01056]\].

Then, chiroptical properties are calculated for all of these selected conformers with one particular AC. For the OR phenomenon, the predicted chiroptical property is the SOR at specific wavelengths. The chiroptical properties predicted for the CD phenomenon are the rotational strengths for each of the transitions. For the corresponding absorption phenomenon, the predicted properties are dipole strengths for each of the transitions. For the ROA phenomena, the properties predicted include normal coordinate derivatives of three different polarizability tensors (namely, electric dipole-electric dipole (EDED), electric dipole-magnetic dipole (EDMD) and electric dipole-electric quadrupole (EDEQ)) for each of the vibrational transitions. The anisotropies of these tensors are combined in an appropriate form to derive the activity associated with the ROA phenomena \[[@B9-molecules-21-01056],[@B32-molecules-21-01056],[@B33-molecules-21-01056]\]. The anisotropy of EDED polarizability derivative tensor determines the activity associated with Raman spectra.

Rotational strengths in the case of CD phenomenon, and activities in the case of ROA phenomenon, are merely the signed numbers that represent integrated band intensities in the CD or ROA spectra. Dipole strengths in the case of absorption associated with CD, or Raman activities in the case of Raman associated with ROA, are positive numbers that represent integrated absorption band intensities in absorption or Raman spectra. They all can only be compared with corresponding integrated band intensities in the experimentally measured spectra. The task of integrating the band areas in the experimentally measured spectra is laborious, and may not provide easy comparison to the predicted quantities when multiple transitions overlap. Therefore, the opposite procedure is used by converting the predicted integrated band intensities into simulated predicted spectra, which can be compared with experimentally observed spectra. Simulation of theoretical spectra involves the assumptions of a band profile (Gaussian, Lorentzian, etc.) and a bandwidth for each of the transitions. For convenience, all transitions are assumed to have the same band profile and one chosen bandwidth. All these simulations can be conveniently undertaken using the spectral comparison software \[[@B23-molecules-21-01056]\]. Since SOR is a cumulative effect from all electronic transitions, there is no simulation involved for theoretical SOR predictions.

For the (6*R*,7*R*,8*S*,10*R*,2'*Z*) structure, sixteen lowest optimized energy conformations were used for ECD and ORD calculations at CAM-B3LYP/aug-cc-pVDZ level and for VCD at B3LYP/aug-cc-pVDZ level of theory.

The calculated chiroptical properties for individual conformers (all with the same predefined AC) are to be weighted with their percent populations, referred to as Boltzmann populations or weights. These Boltzmann weights can be determined from the electronic energies or Gibbs energies obtained in the QC calculations. The Boltzmann weighted predicted ECD and VCD spectra for (6*R*,7*R*,8*S*,10*R*,2'*Z*) diastereomer are shown in [Figure 2](#molecules-21-01056-f002){ref-type="fig"}B and [Figure 3](#molecules-21-01056-f003){ref-type="fig"}B, while the corresponding absorption spectra are shown in [Figure 2](#molecules-21-01056-f002){ref-type="fig"}A and [Figure 3](#molecules-21-01056-f003){ref-type="fig"}A. The predicted population weighted SOR, for (6*R*,7*R*,8*S*,10*R*,2'*Z*) structure, is −44 deg·cc·g^−1^·dm^−1^ at 589 nm.

*Visual analysis of chiroptical spectra*: At the simplest level of spectral comparison analysis, the experimental and predicted chiroptical spectra are visually compared to assess the agreement between them. To facilitate the visual comparison, lines are drawn correlating the bands observed in the experimental spectra with those in the calculated spectra. In the case of ORD, SOR values measured at discrete wavelengths are compared to those obtained in the calculations (keeping in mind that the calculated wavelengths may have been shifted from the experimental wavelengths). From [Figure 2](#molecules-21-01056-f002){ref-type="fig"} and [Figure 3](#molecules-21-01056-f003){ref-type="fig"}, it can be seen that the experimental data for the enantiomer with negative SOR at 589 nm matches that predicted for (6*R*,7*R*,8*S*,10*R*,2'*Z*) diastereomer. Therefore, the AC of centratherin can be assigned \[[@B26-molecules-21-01056]\] as (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*).

Most of the reported chiroptical spectral analyses for chiral drugs were accomplished via visual spectral analyses. A table summarizing the chiral drugs whose ACs were investigated \[[@B34-molecules-21-01056],[@B35-molecules-21-01056],[@B36-molecules-21-01056],[@B37-molecules-21-01056],[@B38-molecules-21-01056],[@B39-molecules-21-01056],[@B40-molecules-21-01056],[@B41-molecules-21-01056],[@B42-molecules-21-01056],[@B43-molecules-21-01056],[@B44-molecules-21-01056],[@B45-molecules-21-01056],[@B46-molecules-21-01056],[@B47-molecules-21-01056],[@B48-molecules-21-01056],[@B49-molecules-21-01056],[@B50-molecules-21-01056],[@B51-molecules-21-01056],[@B52-molecules-21-01056],[@B53-molecules-21-01056],[@B54-molecules-21-01056],[@B55-molecules-21-01056],[@B56-molecules-21-01056],[@B57-molecules-21-01056],[@B58-molecules-21-01056],[@B59-molecules-21-01056],[@B60-molecules-21-01056],[@B61-molecules-21-01056],[@B62-molecules-21-01056],[@B63-molecules-21-01056],[@B64-molecules-21-01056],[@B65-molecules-21-01056],[@B66-molecules-21-01056],[@B67-molecules-21-01056],[@B68-molecules-21-01056],[@B69-molecules-21-01056],[@B70-molecules-21-01056],[@B71-molecules-21-01056],[@B72-molecules-21-01056],[@B73-molecules-21-01056],[@B74-molecules-21-01056],[@B75-molecules-21-01056],[@B76-molecules-21-01056],[@B77-molecules-21-01056],[@B78-molecules-21-01056],[@B79-molecules-21-01056],[@B80-molecules-21-01056],[@B81-molecules-21-01056],[@B82-molecules-21-01056],[@B83-molecules-21-01056],[@B84-molecules-21-01056],[@B85-molecules-21-01056],[@B86-molecules-21-01056],[@B87-molecules-21-01056],[@B88-molecules-21-01056],[@B89-molecules-21-01056],[@B90-molecules-21-01056]\] using chiroptical spectroscopic methods are summarized in [Table 1](#molecules-21-01056-t001){ref-type="table"}. Occasional reviews have also highlighted some of these chiral drugs \[[@B42-molecules-21-01056],[@B65-molecules-21-01056],[@B91-molecules-21-01056],[@B92-molecules-21-01056]\]. There are several natural products with promising medicinal values where ACs were investigated using chiroptical spectroscopy, but it will be unwieldy to review all of them here.

2.5. Spectral Overlap Analysis {#sec2dot5-molecules-21-01056}
------------------------------

Visual spectral analysis does not provide any quantitative measure of agreement between experimental and predicted spectra and may introduce inadvertent user bias. To provide a quantitative measure of agreement, and eliminate the unintended bias, the digital experimental and predicted spectral data are used to calculate the normalized overlap integral between them. If the normalized overlap integral for signed chiroptical spectral data is 1, then the experimental data of the enantiomer used for experimental measurements are reproduced exactly by the AC used for calculations. On the other hand, if the normalized overlap integral for signed chiroptical spectral data is −1, then, the experimental data of the enantiomer used for experimental measurements would be reproduced exactly by the AC, which is opposite to that used for calculations. The normalized overlap integrals for the absorption and Raman spectra, which are between 0 and 1, do not reflect the AC. Nevertheless, it is important to verify that the predicted absorption or Raman spectrum also reproduces the corresponding experimental spectrum (vide infra). Similarity overlap plots for absorption and CD spectra are shown as insets in [Figure 2](#molecules-21-01056-f002){ref-type="fig"}A,B and [Figure 3](#molecules-21-01056-f003){ref-type="fig"}A,B. The ECD spectral overlap analysis (see inset in [Figure 2](#molecules-21-01056-f002){ref-type="fig"}B) yields a ECD spectral overlap of 0.78 for (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*) at a wavelength scale factor of 1.03 and also a overlap of −0.5 at a wavelength scale factor of 0.93. The later value indicates the level of agreement for the opposite enantiomer. This information could not have been obtained from the visual spectral analysis. Even though the overlap for (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*) is higher and that for the opposite enantiomer is lower, one should not be overconfident in assigning the AC from ECD spectral overlap alone (vide infra). The VCD spectral overlap analysis (see inset in [Figure 3](#molecules-21-01056-f003){ref-type="fig"}B) yields a overlap of 0.53 at a frequency scale factor of 0.99 for (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*) and none with opposite signs. Thus any possible assignment of opposite AC is ruled out from the VCD spectral analysis. Comparison of ORD data also supports (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*) assignment \[[@B26-molecules-21-01056]\]. Thus, different chiroptical spectra provide complimentary information that that should be made use of. The spectral overlap analyses discussed in this paragraph have been reported for only a limited number of chiral drugs summarized in [Table 1](#molecules-21-01056-t001){ref-type="table"}.

*Advanced Spectral analysis*: When chiroptical spectra are analyzed, a concomitant analysis for accompanying absorption and Raman spectra should also be provided. This is because some of the fundamental quantities involved are common to both of them. However, undertaking separate analyses for them represents an incomplete enquiry. A complete analysis includes comparison of ratio spectra, i.e., ratio of CD to absorption spectra and ratio of ROA to Raman spectra. The former is called dimensionless dissymmetry factor (DF), while the latter is called dimensionless circular intensity difference (CID). The ratio of ECD spectrum to corresponding absorption spectrum is called electronic dissymmetry factor (EDF) spectrum and the ratio of VCD spectrum to corresponding absorption spectrum is called vibrational dissymmetry factor (VDF) spectrum. The EDF and VDF spectra for centratherin are shown in [Figure 2](#molecules-21-01056-f002){ref-type="fig"}C and [Figure 3](#molecules-21-01056-f003){ref-type="fig"}C. The EDF spectral overlap analysis (see inset to [Figure 2](#molecules-21-01056-f002){ref-type="fig"}C) for (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*) yields a value of 0.85 and no negative values. Note that, in the previous paragraph, we stated that ECD spectra indicated a possibility for the opposite AC assignment, but EDF spectra now rule out that possibility. This example clearly shows the usefulness of EDF spectra. The VCD spectral overlap analysis (see inset to [Figure 3](#molecules-21-01056-f003){ref-type="fig"}C) for (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*) yields a value of 0.62 and no negative values. The overlap values for EDF and VDF are greater than the corresponding values for ECD and VCD. Thus the advanced spectral analysis also suggests the AC of centratherin as (−)~589~-(6*R*,7*R*,8*S*,10*R*,2'*Z*).

The DF spectral analysis provides more insight than CD spectra alone. Furthermore, as literature studies indicate \[[@B69-molecules-21-01056],[@B93-molecules-21-01056]\], the spectral overlap analysis for DF can be particularly useful when a distinction needs to be made out of several possible diastereomers. In addition, unexpected new information may ensue \[[@B94-molecules-21-01056]\] from DF spectral analyses.

Since DF spectral analyses is a new concept, these analyses have not been yet been generally adopted. However, future investigations are recommended to incorporate the DF analyses, as there is more to gain and nothing to lose in such analyses.

Finally, it should be noted that for molecules with several chiral centers with unknown ACs, a unique solution results when only one diastereomeric structure provides the best match between experimental and predicted chiroptical property. But if multiple diastereomeric structures provide similar matches to the experiment, which is a common occurrence, then a given chiroptical property could not have provided the unique solution for AC. This later situation can be avoided if more than one chiroptical property is simultaneously analyzed for the compound of interest. This is because even if multiple diastereomers may possess the same chiroptical property in a given chiroptical method it is unlikely that they will have the same chiroptical property in another chiroptical method.

3. Conclusions {#sec3-molecules-21-01056}
==============

The pharmaceutical industry has widely adopted the chiroptical spectroscopic methods for establishing the ACs of chiral drugs that they are developing. There are some improvements that can be incorporated in to the methods that are being routinely used. The analysis of DF and CID spectra can improve the reliability of the AC assignments, help discriminate among multiple diastereomers and provide better insight. It is pragmatic, and generally important, to investigate more than one chiroptical property for determining the ACs of chiral molecules.
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![The (6*R*,7*R*,8*S*,10*R*,2'*Z*) structure of centratherin \[[@B26-molecules-21-01056]\].](molecules-21-01056-g001){#molecules-21-01056-f001}

![(**A**) Experimental and predicted electronic absorption spectra. Inset shows the similarity overlap plot as a function of wavelength scale factor; (**B**) experimental and predicted ECD spectra. Inset shows the similarity overlap plot as a function of wavelength scale factor; (**C**) experimental and predicted EDF spectra. Inset shows the similarity overlap plot as a function of wavelength scale factor. The experimental spectra are for (−)~589~-centratherin and predicted spectra are for (6*R*,7*R*,8*S*,10*R*,2'*Z*) structure. Data taken from Reference \[[@B26-molecules-21-01056]\].](molecules-21-01056-g002){#molecules-21-01056-f002}

![(**A**) Experimental and predicted vibrational absorption spectra. Inset shows the similarity overlap plot as a function of wavenumber scale factor; (**B**) experimental and predicted VCD spectra. Inset shows the similarity overlap plot as a function of wavenumber scale factor; (**C**) experimental and predicted VDF spectra. Inset shows the similarity overlap plot as a function of wavenumber scale factor. The experimental spectra are for (−)~589~-centratherin and predicted spectra are for (6*R*,7*R*,8*S*,10*R*,2'*Z*) structure. Data taken from Reference \[[@B26-molecules-21-01056]\].](molecules-21-01056-g003){#molecules-21-01056-f003}

molecules-21-01056-t001_Table 1

###### 

Chiral molecules with pharmaceutical applications investigated for their absolute configurations.

  Molecule                                                                                                 Methods Used    Practical Use                                                                  References
  -------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------------------------ -----------------------------------------------------------------------------------
  (1*S*,2*S*,3*R*)-1-acetoxymethyl-2,3,4,4-tetra-methylcyclopentane                                        VCD             pheromone                                                                      \[[@B34-molecules-21-01056]\]
  Aeroplysinin-1                                                                                           VCD, ROA        treatment of antiangiogenic disease                                            \[[@B35-molecules-21-01056]\]
  (*S*)-alaptide                                                                                           ECD, ORD        veterinary ointment                                                            \[[@B90-molecules-21-01056]\]
  (*S*)-alternarlactam                                                                                     VCD             fungal cytotoxin                                                               \[[@B36-molecules-21-01056]\]
  (*S*)-AM3189                                                                                             VCD, OR         diabetes treatment                                                             \[[@B37-molecules-21-01056]\]
  (1*S*,4*S*)-amino-aza-benzimidazolone                                                                    VCD             positive allosteric modulators                                                 \[[@B38-molecules-21-01056]\]
  (*P*)-9-amino-2-cyclopropyl-5-(-2-fluoro-6-methoxyphenyl)-2,3-dihydro-pyrrolo\[3,4-*b*\]quinolin-1-one   VCD             atropisomers of GABA modulator                                                 \[[@B39-molecules-21-01056]\]
  (*S*,*R*,*R*)-Aprepitant                                                                                 VCD             neurokinin 1 (NK1) receptor antagonist,                                        \[[@B40-molecules-21-01056]\]
  (1*R*,5*S*)-1-azabicyclo\[3.1.0\]hexane                                                                  VCD             principle structural fragment of antitumor antibiotics azinomycins A and B     \[[@B41-molecules-21-01056]\]
  (*S*)-AZD624                                                                                             VCD             NK3 antagonist                                                                 \[[@B42-molecules-21-01056]\]
  (*S*)-AZD6765                                                                                            VCD             NMDA antagonist                                                                \[[@B42-molecules-21-01056]\]
  (*R*,*S*) and (*S*,*S*)-Bedaquiline Analogs                                                              ECD             Antituberculosis Agents                                                        \[[@B43-molecules-21-01056]\]
  (*S*)-benzodiazepine                                                                                     VCD             Active component of vasopressin receptor antagonist                            \[[@B44-molecules-21-01056]\]
  (*S*) and (*R*)-2-(3,5-bis(trifluoromethyl)phenyl)-*N*-(4-(2-methylpyridin-4-yl)phenyl)propanamide       VCD, OR         γ-Secretase modulators                                                         \[[@B45-molecules-21-01056]\]
  (2*S*,5*R*,6*S*)-2-Benzyl-5,6-bis(4-bromophenyl)-4-methylmor-pholin-3-one                                VCD, OR         MDM2 inhibitor                                                                 \[[@B46-molecules-21-01056]\]
  (*R*) 8-(4-bromophenyl)-8-ethoxy-8*H*-\[1,4\]thiazino\[3,4-*c*\]\[1,2,4\]-oxadiazol-3-one                ECD, ORD, VCD   Calcium Channel antagonist                                                     \[[@B47-molecules-21-01056],[@B48-molecules-21-01056]\]
  (*S*) and (*R*)-(4-bromophenyl)(imino)(trifluoromethyl)-λ^6^-sulfanone                                   VCD             synthesis of Glucokinase regulatory protein disruptor                          \[[@B49-molecules-21-01056]\]
  (*S*) and (*R*)-(6-bromopyridin-3-yl)(methyl)(trifluoromethyl)-λ^4^-sulfanol                             VCD             synthesis of Glucokinase regulatory protein disruptor                          \[[@B49-molecules-21-01056]\]
  (1*R*,6*S*,9*R*)-Buagafuran                                                                              ECD             antianxiety                                                                    \[[@B50-molecules-21-01056]\]
  (6*R*,7*S*)-chromenotriazolopyrimidine                                                                   VCD             MDM2-p53 inhibitor                                                             \[[@B51-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-2-chlorophenylglycidol                                                       VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-3-chlorophenylglycidol                                                       VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-4-chlorophenylglycidol                                                       VCD,OR,ECD      functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (*S*)-1-\[(4-chlorophenyl)sulfonyl-2-(2-thienyl)pyrrolidine                                              VCD             Calcium Channel antagonist                                                     \[[@B53-molecules-21-01056]\]
  (*S*)-2-(2-chloro-4-pyridinyl)-1,1,1-trifluoro-2-propanol                                                VCD,OR          synthesis of Glucokinase regulatory protein disruptor                          \[[@B54-molecules-21-01056]\]
  (1*S*,2*S*)-Cipralisant (GT-2331)                                                                        VCD             H~3~ antagonist                                                                \[[@B55-molecules-21-01056]\]
  (*S*)-3-cyanomethyl-3-hydroxyindole                                                                      VCD, ECD        antifungal agent                                                               \[[@B56-molecules-21-01056]\]
  (*S*)-desflurane                                                                                         VCD, OR         anesthetic                                                                     
  (*R*)-dichloroprop                                                                                       VCD             herbicide                                                                      \[[@B57-molecules-21-01056],[@B58-molecules-21-01056],[@B59-molecules-21-01056]\]
  (*S*)-dioxybrassinin                                                                                     VCD, ECD        antifungal agent                                                               \[[@B56-molecules-21-01056]\]
  (*S*)-Efavirenz                                                                                          VCD             antiretroviral                                                                 \[[@B40-molecules-21-01056]\]
  (*S*)-enflurane                                                                                          VCD, OR         anesthetic                                                                     \[[@B61-molecules-21-01056]\]
  (1*S*,2*R*)-ephedrine                                                                                    VCD, ROA        antiinflammatory                                                               \[[@B62-molecules-21-01056],[@B63-molecules-21-01056]\]
  (*S*,*S*)-Ethyl 6'-hydroxy-2',3'-dihydrospiro\[cyclopropane-1,1'-indene\]-2-carboxylate                  VCD, OR         Head group in Potent GPR40 Full Agonists                                       \[[@B64-molecules-21-01056]\]
  (*S*)-etodolac                                                                                           VCD             antiinflammtory                                                                \[[@B65-molecules-21-01056]\]
  (1*S*,2*R*,3*S*)-Ezetimibe                                                                               VCD             to treat high cholesterol                                                      \[[@B40-molecules-21-01056]\]
  (*R*,*R*)-Filorexant                                                                                     VCD             Orexin Receptor Antagonist                                                     \[[@B40-molecules-21-01056]\]
  (*S*)-Flecainide                                                                                         VCD             antiarrhythmic                                                                 \[[@B60-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-2-fluorophenylglycidol                                                       VCD,OR,ECD      functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-3-fluorophenylglycidol                                                       VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-4-fluorophenylglycidol                                                       VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine                        VCD             precursor to paroxetine and femoxetine                                         \[[@B52-molecules-21-01056]\]
  (1*R*,5*S*)-Frontalin                                                                                    VCD             pheromone                                                                      \[[@B66-molecules-21-01056]\]
  (*P*)-Gossypol                                                                                           VCD             Antineoplastic agent                                                           \[[@B67-molecules-21-01056]\]
  (*R*)-4-hydroxywarfarin                                                                                  ECD             anticoagulant                                                                  \[[@B68-molecules-21-01056]\]
  (*R*)-6-hydroxywarfarin                                                                                  ECD             anticoagulant                                                                  \[[@B68-molecules-21-01056]\]
  (*R*)-7-hydroxywarfarin                                                                                  ECD             anticoagulant                                                                  \[[@B68-molecules-21-01056]\]
  (*R*)-8-hydroxywarfarin                                                                                  ECD             anticoagulant                                                                  \[[@B68-molecules-21-01056]\]
  (*S*)-Ibuprofen                                                                                          VCD             antiinflammatory                                                               \[[@B40-molecules-21-01056],[@B70-molecules-21-01056]\]
  (7*R*,8*R*,10*S*)-inuloxin A                                                                             ECD, ORD, VCD   phytotxin                                                                      \[[@B71-molecules-21-01056]\]
  (*S*)-Isoflurane                                                                                         VCD, OR, ROA    anesthetic                                                                     \[[@B72-molecules-21-01056],[@B73-molecules-21-01056]\]
  (2*R*,4*S*)-itraconazole                                                                                 VCD             antifungal agent                                                               \[[@B74-molecules-21-01056]\]
  (2*R*,4*S*)-ketoconazole                                                                                 VCD             antifungal agent                                                               \[[@B74-molecules-21-01056]\]
  (*R*)-Laropiprant                                                                                        VCD             prostaglandin D2 receptor 1 antagonist                                         \[[@B40-molecules-21-01056]\]
  (*R*)-malathion                                                                                          VCD             pesticide                                                                      \[[@B75-molecules-21-01056]\]
  (6*S*,10b*R*)-McN 5652-X                                                                                 VCD             transport of seratonin in brain                                                \[[@B76-molecules-21-01056]\]
  (*R*)-mecoprop                                                                                           VCD             herbicide                                                                      \[[@B57-molecules-21-01056],[@B58-molecules-21-01056],[@B59-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-3-methoxyphenylglycidol                                                      VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (*S*)-miconazole                                                                                         VCD             antifungal agent                                                               \[[@B74-molecules-21-01056]\]
  (*R*)-mirtazapine                                                                                        VCD             antidepressant                                                                 \[[@B77-molecules-21-01056]\]
  (*R*)-*N*-(Pyridin-3-yl)-1-(4-(trifluoromethyl)phenyl)-3,4-dihy-droisoquinoline-2(1*H*)-carboxamide      OR              TRPM8 antagonists                                                              \[[@B78-molecules-21-01056]\]
  (*S*)-Naproxen                                                                                           VCD             antiinflammatory                                                               \[[@B60-molecules-21-01056]\]
  (*S*)-*N*-Cyclopropyl-4-methyl-3-\[1-(2,2,2-trifluoro-1-methylethoxy)phthalazin-6-yl\]benzamide          VCD             p38 MAP Kinase Inhibitor                                                       \[[@B79-molecules-21-01056]\]
  (1*S*,2*R*)-*N*-methylephedrine                                                                          VCD             antiinflammatory                                                               \[[@B62-molecules-21-01056]\]
  (1*S*,2*S*)-*N*-methylpseudoephedrine                                                                    VCD             antiinflammatory                                                               \[[@B62-molecules-21-01056]\]
  (1*S*,2*R*)-norephedrine                                                                                 VCD, ROA        antiinflammatory                                                               \[[@B62-molecules-21-01056],[@B63-molecules-21-01056]\]
  (1*S*,2*S*)-norpseudoephedrine,                                                                          VCD, ROA        antiinflammatory                                                               \[[@B62-molecules-21-01056],[@B63-molecules-21-01056]\]
  (*R*,*R*)-Otamixaban                                                                                     VCD             fXa inhibitor                                                                  \[[@B80-molecules-21-01056]\]
  (*S*)-oxadiazol-3-one                                                                                    VCD             calcium channel blocker                                                        \[[@B48-molecules-21-01056]\]
  (4*S*,5*R*,6*R*)-Oxysporone                                                                              ORD, ECD, VCD   herbicides                                                                     \[[@B81-molecules-21-01056]\]
  paclitaxel                                                                                               VCD             chemotherapy                                                                   \[[@B82-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-Phenylglycidol                                                               VCD, OR, ECD    functionality for the synthesis of chiral drugs                                \[[@B52-molecules-21-01056]\]
  (3*S*,4a*R*,8*S*,8a*R*)-Phyllostin                                                                       ORD, ECD, VCD   herbicides                                                                     \[[@B81-molecules-21-01056]\]
  (*S*)-Propranolol                                                                                        VCD             antiarrhythmic                                                                 \[[@B60-molecules-21-01056]\]
  (1*S*,2*S*)-pseudoephedrine                                                                              VCD, ROA        antiinflammatory                                                               \[[@B62-molecules-21-01056],[@B63-molecules-21-01056]\]
  (*S*,*S*), (*R*,*S*), (*S*,*R*) and (*R*,*R*)-6-pyrimidin-2-yl-octahyro-pyrrolo\[2,3-*c*\] pyridine      VCD             core structure for synthesis of functionalized Sarain A                        \[[@B83-molecules-21-01056]\]
  (1*S*,3*R*,4*S*,8*R*,9*S*)-Quinidine                                                                     VCD             antiarrhythmic                                                                 \[[@B60-molecules-21-01056],[@B84-molecules-21-01056]\]
  RAC-109                                                                                                  VCD             antiarrhythmic                                                                 \[[@B60-molecules-21-01056]\]
  (4a*R*,8*S*,8a*R*)-scytolide                                                                             VCD, ORD, ECD   herbicides                                                                     \[[@B81-molecules-21-01056]\]
  (1*S*,2*R*,3a*S*,4*S*,5*R*,7a*S*)-seiricardine A                                                         ECD, ORD, VCD   phytotxin                                                                      \[[@B71-molecules-21-01056]\]
  (*R*,*S*,*R*,*S*,*S*,*R*,*R*)-Simvastatin                                                                VCD             to lower cholesterol and triglycerides                                         \[[@B40-molecules-21-01056]\]
  (*S*) and (*R*)-Tetrahydroisoquinolines                                                                  VCD, OR         RPM8-Antagonists                                                               \[[@B85-molecules-21-01056]\]
  (*R*)-Thalidomide                                                                                        VCD             teratogen                                                                      \[[@B86-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-2-trifluoromethylphenylglycidol                                              VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-3-trifluoromethylphenylglycidol                                              VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (2*R*,3*R*) and (2*S*,3*S*)-4-trifluoromethylphenylglycidol                                              VCD, OR, ECD    functionality that can yield intermediates for the synthesis of chiral drugs   \[[@B52-molecules-21-01056]\]
  (*R*)-1,3,5-triphenyl-2-pyrazoline                                                                       ECD, VCD        anti depressant                                                                \[[@B87-molecules-21-01056]\]
  Valinomycin                                                                                              VCD, ROA        transport antibiotic                                                           \[[@B88-molecules-21-01056],[@B89-molecules-21-01056]\]
  (*R*)-warfarin                                                                                           ECD             anticoagulant                                                                  \[[@B68-molecules-21-01056]\]
